Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | MDM2 inhibition in AML: trial updates

Marina Konopleva • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Cytarabine Idasanutlin Venetoclax
MIRROS

The inhibition of MDM2 blocks the MDM2-p53 protein-protein interaction, allowing p53 to signal for apoptosis; however, there have been challenges with implementing this approach as a therapy. Here, Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest data regarding MDM2 inhibitor therapy for acute myeloid leukemia (AML); in combination with cytarabine (MIRROS; NCT02545283) or in combination with venetoclax (NCT02670044). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals